BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028

BridgeBio Oncology Therapeutics, Inc.

2025-Q3 EPS reported -$6.49 vs consensus -$0.40 ▼ miss (-1532.3%)

Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.
Cash, equivalents and marketable securities $468.3M; runway expected into 2028.
Closed SPAC business combination with Helix Acquisition Corp II on Aug 11, 2025; began trading on Nasdaq as BBOT.
Appointed Uneek Mehra as CFO in July 2025.
Three Phase 1 trials advancing (BBO-8520, BBO-10203, BBO-11818); initial clinical data readouts expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.